Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers

Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers

Abstract This phase I clinical trial (NCT01935843) is to evaluate the safety, feasibility, and activity of chimeric antigen receptor-engineered T cell (CART) immunotherapy targeting human epidermal growth factor receptor 2 (HER2) in patients with advanced biliary tract cancers (BTCs) and pancreatic...

Full description

Bibliographic Details
Main Authors: Kaichao Feng, Yang Liu, Yelei Guo, Jingdan Qiu, Zhiqiang Wu, Hanren Dai, Qingming Yang, Yao Wang, Weidong Han
Format: Article
Language:English
Published: Oxford University Press 2017-07-01
Series:Protein & Cell
Subjects:
HER2
CART
biliary tract cancers
pancreatic cancers
clinical trial
Online Access:http://link.springer.com/article/10.1007/s13238-017-0440-4

Internet

http://link.springer.com/article/10.1007/s13238-017-0440-4

Similar Items